Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Lexicon Pharmaceuticals reports strong Q4 performance and eyes growth

Lexicon Pharmaceuticals showcased promising drug candidates and financial stability in Q4 2022.
While facing challenges in revenue generation and expense management, the company is strategically positioned for growth.
Opportunities lie in commercial launches, Phase 3 advancements, and potential partnerships to drive future success.
Overall, Lexicon's focus on maximizing asset value and advancing key drugs positions them for long-term success in the pharmaceutical market.

Lexicon Pharmaceuticals reports robust Q1 performance and eyes market expansion

Lexicon Pharmaceuticals showcased strong financials, promising drug candidates, and strategic confidence in market success.
Challenges lie in market penetration strategies, FDA feedback, and successful commercialization amidst competition.
Opportunities abound with upcoming sotagliflozin launch, advancing LX9211, and leveraging unique data for growth.

Lexicon Pharmaceuticals reports strong Q2 earnings and advances key treatments

Lexicon Pharmaceuticals demonstrated financial stability and strategic progress in Q2 2023, supported by strong cash reserves and key regulatory milestones.
The company's focus on patient-centric initiatives and upcoming product launches positions it for sustained growth and market success.
Challenges in market penetration and revenue realization require targeted strategies, while opportunities in market expansion and pipeline development offer avenues for growth.
Overall, Lexicon Pharmaceuticals shows promise with a solid foundation for future success, driven by innovation and market-focused strategies.

Lexicon Pharmaceuticals reports Q3 loss, highlights INPEFA progress and global expansion

Lexicon Pharmaceuticals faces challenges in market access and inventory trends while capitalizing on opportunities through geographic expansion and potential partnerships. The company's financial performance in Q3 2023 showed increased expenses but progress in prescription demand for INPEFA.

Lexicon Pharmaceuticals reports strong Q1 performance and growth opportunities

Lexicon Pharmaceuticals showcased strong performance and progress in Q1 2024, with a focus on product launches and market access.
Despite challenges in achieving full access and addressing specific patient needs, the company remains optimistic about future growth opportunities.
Positive customer feedback, ongoing pipeline advancements, and strategic market considerations position Lexicon well for future success and sales acceleration.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ALX Onconology Holdings Inc

Athene Holding Ltd. Class A

Biglari Hlds

Grid Dynamics Holdings Inc

 StoneX Group

Southern National Bancorp of Virginia

Net 1 UEPS Technologies

AMERCO

Viatris

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as has been the case as new COVID-19 cases surge.

Notable Insider Buys of the Past Week: Mylan, Sonabank, Steak 'n Shake, U-Haul And More

THE WOODLANDS, Texas, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has entered a collaboration enabling the use by AC Bioscience LTD of preclinical and clinical data for LX2931 without granting any right or license under any of Lexicon's patent rights for the compound. LX2931 is a small molecule sphingosine-1-phosphate (S1P) lyase inhibitor that is currently not in active development at Lexicon.

Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience

More clarification seems warranted for the company's shareholder-diluting move.

Why Lexicon Pharmaceuticals Flopped on Friday

THE WOODLANDS, Texas, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it had entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale, in a registered direct offering, of 20,312,500 shares of its common stock, par value $0.001 (the “Common Stock”), at a price of $3.20 per share, for aggregate gross proceeds to the Company of $65,000,000 before deducting fees to the placement agent and other estimated offering expenses payable by the Company. The transaction is expected to close on December 16, 2020, subject to satisfaction of customary closing conditions.

Lexicon Announces Offering of Common Stock

THE WOODLANDS, Texas, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of LX9211 in diabetic peripheral neuropathic pain.

Lexicon Pharmaceuticals Receives Fast Track Designation From the FDA for LX9211 for Diabetic Peripheral Neuropathic Pain

Investors need to pay close attention to Lexicon Pharmaceuticals (LXRX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Lexicon Pharmaceuticals (LXRX) Stock?

Lexicon Pharmaceuticals (NASDAQ: LXRX) is currently up 93.64% to a price of $3.3. Tuesday the stock has been traded at a volume of 163.00 million, about 3138.31% of its recent 30-day volume average of 5.19 million.

Why Lexicon Pharmaceuticals's Stock is Up During Today's Session

Lexicon Pharmaceuticals (LXRX) stock is soaring higher on Tuesday after getting an upgrade from Citi analyst Yigal Nochomovitz. The post LXRX Stock: Why Lexicon Pharmaceuticals Is Soaring Tuesday appeared first on InvestorPlace.

LXRX Stock: Why Lexicon Pharmaceuticals Is Soaring Tuesday

Lexicon Pharmaceuticals (LXRX) news for Tuesday includes LXRX stock soaring higher on results from a Phase 3 clinical trial. The post Lexicon Pharmaceuticals News: Why LXRX Stock Is Soaring 43% Today appeared first on InvestorPlace.

Lexicon Pharmaceuticals News: Why LXRX Stock Is Soaring 43% Today

Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies

Results From SOLOIST and SCORED Outcomes Studies Presented at Late-Breaking Science Session of American Heart Association Scientific Sessions and Published in The New England Journal of Medicine

THE WOODLANDS, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following conference:

Lexicon Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference

Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q3 2020 Results - Earnings Call Transcript

Lexicon (LXRX) delivered earnings and revenue surprises of 57.78% and -94.43%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (LXRX) Q3 Earnings Beat Estimates

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) rose 5.7% in pre-market trading after the company reported Q3 results.

Lexicon Pharmaceuticals: Q3 Earnings Insights

Conference Call and Webcast at 8:00 am Eastern Time Conference Call and Webcast at 8:00 am Eastern Time

Lexicon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical Update

Lexicon Has Reduced Its Outstanding Debt by Approximately 90% in Third Quarter 2020 Lexicon Has Reduced Its Outstanding Debt by Approximately 90% in Third Quarter 2020

Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness

Lexicon Receives $160.4 Million at Closing

Lexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera Therapeutics

THE WOODLANDS, Texas, Sept.  04, 2020  (GLOBE NEWSWIRE) --  Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX), announced today the commencement of patient dosing with blinded study drug in RELIEF-DPN-1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of diabetic peripheral neuropathic pain. LX9211 is a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1).

Lexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain

THE WOODLANDS, Texas, Sept.  03, 2020  (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following conferences:

Lexicon Pharmaceuticals to Participate in the Citi 15ᵗʰ Annual BioPharma Virtual Conference and the Wells Fargo 2020 Virtual Healthcare Conference

Dynavax Technologies

iShares Nasdaq Biotechnology ETF

ImmunoGen

Viking Therapeutics

Xencor

The second half of 2020 is well underway, and with markets recovering, one of the strongest industries leading the charge has been biotech.

5 Speculative Biotechs With 50% to 300% Implied Upside

Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q2 2020 Results - Earnings Call Transcript

Phase 2 Study for Diabetic Peripheral Neuropathic Pain Underway, Additional Studies Planned in Other Areas of Neuropathic Pain

Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program

Lexicon to Receive Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract Cancer Lexicon to Receive Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract Cancer

Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELO

Biogen

Coherus BioSciences

Gen Digital Inc

Salarius Pharmaceuticals Inc

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects.

5 Value Stocks In The Healthcare Sector

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Lexicon Pharmaceuticals Stock (LXRX)